Topline data from our Phase 3 study for Tourette syndrome continues to make news!?
关于我们
Emalex Biosciences was created to develop new treatments for CNS disorders. It is in late-stage development of a new class of drug for patients with Tourette syndrome and other conditions that have limited treatment options.?
- 网站
-
https://www.emalexbiosciences.com
Emalex Biosciences的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Chicago，Illinois
- 类型
- 私人持股
- 创立
- 2018
- 领域
- Pharmaceutical、Biopharmaceutical、Innovation、Research and development、Central Nervous System (CNS) disorders和Tourette Syndrome
地点
-
主要
获取路线
330 N Wabash Ave
Suite 3500
US，Illinois，Chicago，60611
Emalex Biosciences员工
动态
-
Today we announced positive topline data from our Phase 3 registrational study of an investigational therapeutic to reduce tics for people with Tourette syndrome. This is an outstanding milestone in our commitment to helping people with this chronic neurodevelopmental disorder. Read more: https://lnkd.in/g4VAvvPJ #TouretteSyndrome
-
-
Honored to be named “Neuroscience Therapeutics Company of the Year” by BioTech Breakthrough. This award recognizes standout life sciences and biotechnology companies around the world that address a true need, solve a complex or critical problem, or seize an opportunity and create or revolutionize a new market or industry. At Emalex, we are proud of our work to improve the lives of people living with Tourette Syndrome, a condition with high unmet needs and limited treatment options. Read more about the awards: https://lnkd.in/dRz2kiM7
Emalex Biosciences is the “Neuroscience Therapeutics Company Of The Year” for innovating solutions that improve the lives of people living with chronic CNS conditions like Tourette Syndrome. www.emalexbiosciences.com #BioTechBreakthrough #Tourettes
-
Hope to see you in Philly at the International Parkinson and Movement Disorder Society's International Congress!
-
-
Tim Rudolphi recently joined Emalex as our Chief Commercial Officer. He is responsible for developing and executing our commercial strategy and product launches.?His extensive commercial expertise and broad leadership experience in large and small pharma organizations are vital to our commercial preparations. Welcome Tim! https://lnkd.in/gY8VkkSX
-